Granite Investment Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

Granite Investment Partners’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,058	Closed	-$15.7K	–	271
2024 Q1	$15.7K	Buy	+1,058	New	+$14.3K	﹤0.01%	256
2020 Q1	–	Sell	-1,430	Closed	-$31K	–	304
2019 Q4	$31K	Sell	1,430 -9,609	-87%	-$198K	﹤0.01%	285
2019 Q3	$206K	Buy	11,039 +3,828	+53%	+$79.1K	0.01%	320
2019 Q2	$188K	Sell	7,211 -6,333	-47%	-$143K	0.01%	332
2019 Q1	$348K	Buy	13,544 +6,333	+88%	+$145K	0.02%	320
2018 Q4	$166K	Hold	7,211	–	–	0.01%	325
2018 Q3	$231K	Buy	+7,211	New	+$216K	0.01%	295
2013 Q3	–	Sell	-10,614	Closed	-$354K	–	257
2013 Q2	$354K	Buy	+10,614	New	+$481K	0.06%	194

Other funds holding RIGL

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Granite Investment Partners's RIGL Position: Q2 2024 in Review

Granite Investment Partners sold out of Rigel Pharmaceuticals (RIGL) in Q2 2024, closing a stake of 1,058 shares — an estimated $15.7K sold.

Granite Investment Partners first reported a position in RIGL in Q2 2013 and held it in 8 quarters. The position peaked at $354K in Q2 2013. 91 funds tracked by Wall St. Rank hold RIGL as of Q2 2024.

Granite Investment Partners reported no remaining Rigel Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Granite Investment Partners sold 1,058 Rigel Pharmaceuticals shares in Q2 2024, an estimated $15.7K.
Granite Investment Partners first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 8 quarters.
Granite Investment Partners's Rigel Pharmaceuticals position peaked at $354K in Q2 2013.
91 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2024.

Based on Granite Investment Partners's 13F filing for Q2 2024, filed 12 Aug 2024.